X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-10-22 | GALT | Galectin Therapeutics Inc | 10X Fund, L.P. | 10% | S - Sale | $4.94 | -50,000 | 5,872,207 | -1% | -$246,800 | ||||||
2025-10-23 | KALA | Kala Bio, Inc. | Iwicki Mark T | Dir | S - Sale | $0.81 | -154,894 | 103,540 | -60% | -$125,464 | ||||||
| M | 2025-10-22 | KALA | Kala Bio, Inc. | Reumuth Mary | CFO | S - Sale | $0.83 | -33,197 | 28,906 | -53% | -$27,544 | |||||
2025-10-22 | KALA | Kala Bio, Inc. | Bazemore Todd | Dir | S - Sale | $0.83 | -47,768 | 35,933 | -57% | -$39,647 | ||||||
2025-10-22 | KALA | Kala Bio, Inc. | Brazzell Romulus K | SEE REMARKS | S - Sale | $0.83 | -46,748 | 35,952 | -57% | -$38,801 | ||||||
2025-10-22 | KALA | Kala Bio, Inc. | Kharabi Darius | CHIEF BUSINESS OFFICER | S - Sale | $0.83 | -20,806 | 41,760 | -33% | -$17,269 | ||||||
2025-06-06 | BOLT | Bolt Biotherapeutics, Inc. | Nemec Sarah | SVP, Finance, PAO | P - Purchase | $5.49 | +125 | 23,943 | +1% | +$687 | ||||||
2025-06-06 | BOLT | Bolt Biotherapeutics, Inc. | Quinn William P. | Pres, CEO, CFO | P - Purchase | $5.49 | +125 | 42,188 | 0% | +$687 | ||||||
| M | 2025-10-22 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $40.53 | -18,899 | 71,840 | -21% | -$765,941 | |||||
| D | 2025-10-22 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale+OE | $47.54 | -2,209 | 38,867 | -5% | -$105,015 | |||||
2025-10-23 | ALZN | Alzamend Neuro, Inc. | McGrath Lynne Fahey | Dir | S - Sale | $2.29 | -30 | 25 | -55% | -$69 | ||||||
2025-10-22 | IRON | Disc Medicine, Inc. | Ai Dmi LLC | 10% | S - Sale | $80.47 | -744,047 | 2,814,379 | -21% | -$59,873,462 | ||||||
2025-10-21 | SMMT | Summit Therapeutics Inc. | Xia Yu | Dir | P - Purchase | $18.74 | +533,617 | 32,057,147 | +2% | +$9,999,983 | ||||||
2025-10-23 | TTRX | Turn Therapeutics Inc. | Chaudhary Zuraiz | See Remarks | P - Purchase | $4.95 | +5,050 | 5,050 | New | +$24,998 | ||||||
2025-10-23 | TTRX | Turn Therapeutics Inc. | Golden Arthur F | Dir | P - Purchase | $4.95 | +20,202 | 30,202 | +202% | +$100,000 | ||||||
2025-10-21 | NEUP | Neuphoria Therapeutics Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $5.14 | +639,110 | 875,328 | +271% | +$3,283,108 | ||||||
2025-10-21 | BGMS | Bio Green Med Solution, Inc. | Fitters Diversified Berhad | 10% | S - Sale | $3.01 | -92,352 | 279,248 | -25% | -$277,518 | ||||||
| D | 2025-10-21 | APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | CFO | S - Sale+OE | $28.03 | -10,000 | 171,332 | -6% | -$280,300 | |||||
2025-10-21 | SMMT | Summit Therapeutics Inc. | Duggan Robert W | Co-CEO, 10% | P - Purchase | $18.74 | +26,680 | 606,105,809 | 0% | +$499,983 | ||||||
2025-10-21 | SMMT | Summit Therapeutics Inc. | Zanganeh Mahkam | Co-CEO, 10% | P - Purchase | $18.74 | +26,680 | 606,105,809 | 0% | +$499,983 | ||||||
2025-10-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $22.08 | -12,500 | 915,188 | -1% | -$276,025 | ||||||
| M | 2025-10-20 | RANI | Rani Therapeutics Holdings, Inc. | South Cone Investments Limited Partnership | 10% | S - Sale | $2.65 | -5,923,000 | 2,379,194 | -71% | -$15,711,315 | |||||
2025-10-20 | BGMS | Bio Green Med Solution, Inc. | Fitters Diversified Berhad | 10% | S - Sale | $3.09 | -108,107 | 371,600 | -23% | -$333,834 | ||||||
| DM | 2025-10-21 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $424.96 | -8,000 | 644,489 | -1% | -$3,399,650 | |||||
| D | 2025-10-21 | SION | Sionna Therapeutics, Inc. | Cloonan Michael | Pres, CEO | S - Sale+OE | $36.26 | -99,800 | 547,343 | -15% | -$3,618,560 | |||||
| DM | 2025-10-20 | KNSA | Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | COB, CEO | S - Sale+OE | $38.86 | -257,969 | 221,589 | -54% | -$10,023,532 | |||||
| D | 2025-10-20 | KNSA | Kiniksa Pharmaceuticals International, Plc | Megna Michael R | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $38.87 | -50,490 | 27,046 | -65% | -$1,962,781 | |||||
| D | 2025-10-20 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $94.91 | -5,000 | 49,086 | -9% | -$474,550 | |||||
| D | 2025-10-21 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $58.22 | -2,105 | 140,610 | -1% | -$122,553 | |||||
2025-10-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $21.33 | -12,500 | 902,892 | -1% | -$266,654 | ||||||
2025-10-20 | MBX | Mbx Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO | P - Purchase | $13.64 | +20,000 | 949,674 | +2% | +$272,790 | ||||||
| DM | 2025-10-17 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $40.37 | -16,775 | 90,739 | -16% | -$677,198 | |||||
2025-10-21 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $34.22 | -88,878 | 2,995,602 | -3% | -$3,041,683 | ||||||
| D | 2025-10-20 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Altmeyer Anne | Dir | S - Sale+OE | $20.50 | -1,060 | 6,191 | -15% | -$21,730 | |||||
| D | 2025-10-20 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $427.41 | -22,500 | 2,648 | -89% | -$9,616,703 | |||||
| D | 2025-10-20 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $4.97 | -6,500 | 0 | -100% | -$32,287 | |||||
| M | 2025-10-16 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $32.30 | -286,369 | 3,084,480 | -8% | -$9,251,102 | |||||
| M | 2025-10-16 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.73 | -131,311 | 4,028,036 | -3% | -$227,675 | |||||
| D | 2025-10-17 | JNJ | Johnson & Johnson | Reed John C | EVP, Innovative Medicine, R, D | S - Sale+OE | $192.71 | -21,721 | 10,658 | -67% | -$4,185,793 | |||||
| M | 2025-10-16 | LVTX | Lava Therapeutics Nv | Cooperatieve Gilde Healthcare IV U.A. | 10% | S - Sale | $1.47 | -2,871,370 | 1,947,781 | -60% | -$4,224,719 | |||||
| M | 2025-10-15 | BGMS | Bio Green Med Solution, Inc. | Kua Khai Loon | 10% | S - Sale | $4.33 | -95,683 | 242,477 | -28% | -$414,295 | |||||
2025-10-16 | BGMS | Bio Green Med Solution, Inc. | Fitters Diversified Berhad | 10% | S - Sale | $5.50 | -26,051 | 479,707 | -5% | -$143,281 | ||||||
2025-10-17 | MBX | Mbx Biosciences, Inc. | Hoerter Steven L. | Dir | P - Purchase | $13.25 | +20,000 | 20,000 | New | +$264,984 | ||||||
| DM | 2025-10-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $427.63 | -8,000 | 644,489 | -1% | -$3,421,037 | |||||
| D | 2025-10-16 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $112.03 | -14,437 | 8,509 | -63% | -$1,617,337 | |||||
2025-10-17 | GOVX | Geovax Labs, Inc. | Spencer John N Jr | Dir | P - Purchase | $0.55 | +10,000 | 21,402 | +88% | +$5,498 | ||||||
| D | 2025-10-16 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $431.50 | -11,000 | 36,781 | -23% | -$4,746,494 | |||||
| DM | 2025-10-15 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $16.99 | -851,383 | 1,504,959 | -36% | -$14,467,502 | |||||
2025-10-15 | KROS | Keros Therapeutics, Inc. | Pontifax Management 4 G.P. (2015) Ltd. | 10% | S - Sale | $17.75 | -4,787,331 | 10,500 | -100% | -$84,975,125 | ||||||
| DM | 2025-10-15 | SION | Sionna Therapeutics, Inc. | Cloonan Michael | Pres, CEO | S - Sale+OE | $31.28 | -25,200 | 547,343 | -4% | -$788,153 | |||||
| M | 2025-10-15 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $85.97 | -93,585 | 436,549 | -18% | -$8,045,252 | |||||
| D | 2025-10-16 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $90.63 | -27,000 | 249,062 | -10% | -$2,447,021 | |||||
| DM | 2025-10-15 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $90.72 | -28,000 | 49,086 | -36% | -$2,540,290 | |||||
| D | 2025-10-15 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $90.04 | -14,205 | 65,963 | -18% | -$1,279,018 | |||||
| D | 2025-10-15 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $85.57 | -1,683 | 61,734 | -3% | -$144,014 | |||||
2025-10-16 | SDGR | Schrodinger, Inc. | Dugan Margaret | Chief Medical Officer | S - Sale | $21.07 | -1,395 | 24,574 | -5% | -$29,387 | ||||||
| D | 2025-10-15 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | CHRO | S - Sale+OE | $50.15 | -20,000 | 97,130 | -17% | -$1,003,058 | |||||
2025-10-16 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $25.22 | -5,000 | 173,866 | -3% | -$126,100 | ||||||
2025-10-16 | PRAX | Praxis Precision Medicines, Inc. | Adage Capital Management, L.P. | 10% | S - Sale | $105.76 | -313,910 | 4,421,660 | -7% | -$33,198,124 | ||||||
| D | 2025-10-15 | AQST | Aquestive Therapeutics, Inc. | Jung Cassie | COO | S - Sale+OE | $7.01 | -67,575 | 242,771 | -22% | -$473,701 | |||||
2025-10-15 | AQST | Aquestive Therapeutics, Inc. | Kraus Carl N | Chief Medical Officer | S - Sale | $7.00 | -20,272 | 282,475 | -7% | -$141,904 | ||||||
2025-10-15 | AQST | Aquestive Therapeutics, Inc. | Boyd Peter E. | See Remarks | S - Sale | $7.00 | -10,000 | 268,323 | -4% | -$70,000 | ||||||
| D | 2025-10-16 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale+OE | $73.62 | -53 | 30,709 | 0% | -$3,902 | |||||
2025-10-15 | IONS | Ionis Pharmaceuticals Inc | Parshall B Lynne | Dir | S - Sale | $71.74 | -5,000 | 61,344 | -8% | -$358,722 | ||||||
| DM | 2025-10-15 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale+OE | $73.06 | -7,263 | 17,494 | -29% | -$530,638 | |||||
| DM | 2025-10-14 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale+OE | $72.13 | -23,900 | 56,826 | -30% | -$1,723,987 | |||||
2025-10-14 | BGMS | Bio Green Med Solution, Inc. | Ong Yee Lung | 10% | S - Sale | $6.00 | -135,793 | 268,672 | -34% | -$814,758 | ||||||
2025-10-16 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $60.03 | -5,000 | 367,274 | -1% | -$300,150 | ||||||
| D | 2025-10-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $18.16 | -12,500 | 198,141 | -6% | -$226,943 | |||||
| D | 2025-10-14 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $37.67 | -12,368 | 28,684 | -30% | -$465,843 | |||||
| DM | 2025-10-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $433.30 | -8,000 | 644,489 | -1% | -$3,466,417 | |||||
2025-10-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $25.79 | -8,500 | 409,642 | -2% | -$219,196 | ||||||
2025-10-15 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $25.81 | -10,916 | 702,369 | -2% | -$281,729 | ||||||
2025-10-07 | EBS | Emergent Biosolutions Inc. | Glessner Coleen | EVP, Quality, Ethics,, CPL | S - Sale | $10.00 | -30,608 | 144,319 | -17% | -$306,080 | ||||||
2025-10-16 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.49 | -249 | 1,189,818 | 0% | -$1,366 | ||||||
| D | 2025-10-15 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $22.41 | -6,000 | 110,886 | -5% | -$134,439 | |||||
2025-10-14 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $3.96 | -28,918 | 67,006 | -30% | -$114,581 | ||||||
| M | 2025-10-13 | LVTX | Lava Therapeutics Nv | Cooperatieve Gilde Healthcare IV U.A. | 10% | S - Sale | $1.51 | -475,027 | 4,819,151 | -9% | -$718,721 | |||||
2025-10-10 | APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Dir | S - Sale | $23.72 | -31,092 | 153,606 | -17% | -$737,536 | ||||||
| M | 2025-10-13 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.68 | -153,816 | 4,159,347 | -4% | -$259,164 | |||||
2025-10-13 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale | $42.01 | -10,758 | 116,865 | -8% | -$451,984 | ||||||
2025-10-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $42.67 | -15,100 | 831,305 | -2% | -$644,327 | ||||||
2025-10-15 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale | $43.01 | -10,369 | 71,155 | -13% | -$445,982 | ||||||
| D | 2025-10-15 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $31.53 | -9,000 | 73,740 | -11% | -$283,776 | |||||
| M | 2025-10-10 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $30.47 | -194,932 | 3,370,849 | -5% | -$5,939,784 | |||||
| D | 2025-10-10 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $87.54 | -2,200 | 0 | -100% | -$192,588 | |||||
| DM | 2025-10-13 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO | S - Sale+OE | $18.88 | -24,734 | 309,892 | -7% | -$466,936 | |||||
| D | 2025-10-14 | QNRX | Quoin Pharmaceuticals, Ltd. | Langer Dennis | Dir | P - Purchase | $8.49 | +15,152 | 15,153 | >999% | +$128,640 | |||||
| D | 2025-10-13 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $23.41 | -7,839 | 590,517 | -1% | -$183,511 | |||||
| D | 2025-10-13 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $23.41 | -11,630 | 352,646 | -3% | -$272,258 | |||||
| D | 2025-10-13 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $23.41 | -4,900 | 153,462 | -3% | -$114,709 | |||||
| D | 2025-10-13 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $23.41 | -5,327 | 247,930 | -2% | -$124,705 | |||||
2025-10-13 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale | $23.41 | -1,238 | 185,411 | -1% | -$28,982 | ||||||
2025-10-06 | SPRB | Spruce Biosciences, Inc. | Parkman Healthcare Partners LLC | 10% | P - Purchase | $17.91 | +256 | 1,050 | +32% | +$4,585 | ||||||
2025-10-06 | SPRB | Spruce Biosciences, Inc. | Parkman Healthcare Partners LLC | 10% | S - Sale | $19.14 | -257 | 1,050 | -20% | -$4,920 | ||||||
| D | 2025-10-13 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $23.41 | -20,261 | 2,621,235 | -1% | -$474,310 | |||||
| D | 2025-10-13 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $23.41 | -3,670 | 175,690 | -2% | -$85,915 | |||||
| DM | 2025-10-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $438.95 | -8,000 | 644,489 | -1% | -$3,511,604 | |||||
| DM | 2025-10-13 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $87.36 | -40,000 | 61,734 | -39% | -$3,494,303 | |||||
| D | 2025-10-13 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $440.35 | -22,500 | 2,648 | -89% | -$9,907,963 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |